(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
5 days till quarter result
(bmo 2024-04-25)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...
Stats | |
---|---|
Today's Volume | 458.00 |
Average Volume | 1 248.00 |
Market Cap | 77.71B |
EPS | €0 ( 2024-02-05 ) |
Next earnings date | ( €0 ) 2024-04-25 |
Last Dividend | €0.750 ( 2023-09-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 14.77 |
ATR14 | €0.139 (0.22%) |
Gilead Sciences Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Gilead Sciences Inc Financials
Annual | 2023 |
Revenue: | €27.12B |
Gross Profit: | €20.62B (76.04 %) |
EPS: | €4.54 |
Q4 | 2023 |
Revenue: | €7.11B |
Gross Profit: | €5.02B (70.62 %) |
EPS: | €1.150 |
Q3 | 2023 |
Revenue: | €7.05B |
Gross Profit: | €5.49B (77.80 %) |
EPS: | €1.750 |
Q2 | 2023 |
Revenue: | €6.60B |
Gross Profit: | €5.16B (78.15 %) |
EPS: | €0.840 |
Financial Reports:
No articles found.
Gilead Sciences Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.730 (N/A) |
€0.730 (N/A) |
€0.750 (N/A) |
€0.750 (N/A) |
€0.750 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.430 | 2015-06-12 |
Last Dividend | €0.750 | 2023-09-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 34 | -- |
Total Paid Out | €20.74 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.47 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.86 | |
Div. Directional Score | 8.78 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WAC.DE | Ex Dividend Junior | 2023-05-29 | Annually | 0 | 0.00% | |
GIL.DE | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% | |
PEP.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
BMW.DE | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
HRPK.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
SBS.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
CSH.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
KRN.DE | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
3T70.F | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
TLX.DE | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.209 | 1.500 | 5.82 | 8.73 | [0 - 0.5] |
returnOnAssetsTTM | 0.0912 | 1.200 | 6.96 | 8.35 | [0 - 0.3] |
returnOnEquityTTM | 0.260 | 1.500 | 8.22 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.672 | -1.000 | 3.28 | -3.28 | [0 - 1] |
currentRatioTTM | 1.426 | 0.800 | 7.87 | 6.30 | [1 - 3] |
quickRatioTTM | 1.057 | 0.800 | 8.49 | 6.79 | [0.8 - 2.5] |
cashRatioTTM | 0.539 | 1.500 | 8.11 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.402 | -1.500 | 3.30 | -4.94 | [0 - 0.6] |
interestCoverageTTM | 8.06 | 1.000 | 8.13 | 8.13 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.42 | 2.00 | 7.86 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.95 | 2.00 | 7.03 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.094 | -1.500 | 5.62 | -8.43 | [0 - 2.5] |
grossProfitMarginTTM | 0.760 | 1.000 | 0.661 | 0.661 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.280 | 1.000 | 6.39 | 6.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.320 | 1.000 | 9.33 | 9.33 | [0.2 - 2] |
assetTurnoverTTM | 0.436 | 0.800 | -0.424 | -0.339 | [0.5 - 2] |
Total Score | 10.70 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 15.09 | 1.000 | 8.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.260 | 2.50 | 8.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.95 | 2.00 | 8.02 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.41 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.42 | 2.00 | 7.86 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.672 | 1.500 | 3.28 | -3.28 | [0 - 1] |
pegRatioTTM | 0.717 | 1.500 | 8.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.295 | 1.000 | 5.12 | 0 | [0.1 - 0.5] |
Total Score | 6.86 |
Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators